Novak Djokovic Reveals He’s Been ‘Dealing With (A Health Issue) For Many Years Now’ - Forbes

Seasonal depression often surfaces in the fall and winter, but therapists say proactive measures can significantly reduce the severity of symptoms. Seasonal affective disorder (SAD) is brought on by the changing seasons. It can be an overwhelming, jarring type of depression. Most people, when first dealing with it, aren’t sure how to cope with seasonal depression. They begin feeling sapped of energy and interest during the fall, and their condition continues to worsen as winter progresses. The depressive symptoms typically self-resolve during the springtime and remain minimal throughout the summer months. It is also important to remember that winter depression or winter blues is a lesser form of SAD.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.